MA46677A - Co-cristaux, sels et formes solides de ténofovir alafénamide - Google Patents

Co-cristaux, sels et formes solides de ténofovir alafénamide

Info

Publication number
MA46677A
MA46677A MA046677A MA46677A MA46677A MA 46677 A MA46677 A MA 46677A MA 046677 A MA046677 A MA 046677A MA 46677 A MA46677 A MA 46677A MA 46677 A MA46677 A MA 46677A
Authority
MA
Morocco
Prior art keywords
crystals
salts
solid forms
tenofovir alafenamide
alafenamide
Prior art date
Application number
MA046677A
Other languages
English (en)
Inventor
Bing Shi
Zhuoyi Su
Fang Wang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA46677A publication Critical patent/MA46677A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046677A 2015-06-17 2016-06-13 Co-cristaux, sels et formes solides de ténofovir alafénamide MA46677A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562180963P 2015-06-17 2015-06-17

Publications (1)

Publication Number Publication Date
MA46677A true MA46677A (fr) 2019-09-11

Family

ID=56204022

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046677A MA46677A (fr) 2015-06-17 2016-06-13 Co-cristaux, sels et formes solides de ténofovir alafénamide

Country Status (8)

Country Link
US (2) US9777028B2 (fr)
EP (2) EP3310797A1 (fr)
JP (1) JP2018524308A (fr)
AU (2) AU2016277859B2 (fr)
CA (1) CA2987085A1 (fr)
HK (1) HK1252631A1 (fr)
MA (1) MA46677A (fr)
WO (1) WO2016205141A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170123308A (ko) 2014-12-26 2017-11-07 에모리 유니버시티 N4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
WO2018115046A1 (fr) * 2016-12-23 2018-06-28 Sandoz Ag Formes solides cristallines de ténofovir alafénamide
CN108341841B (zh) * 2017-01-22 2020-07-17 成都倍特药业股份有限公司 一种替诺福韦艾拉酚胺与门冬氨酸的盐
TWI714820B (zh) 2017-01-31 2021-01-01 美商基利科學股份有限公司 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
US20190374557A1 (en) * 2017-02-28 2019-12-12 Alexandre Vasilievich Ivachtchenko Cyclobutyl (S)-2-[[[(R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, and production process and application thereof
BR122022008466B1 (pt) 2017-12-07 2023-12-05 Emory University Uso de um composto
CN108997428B (zh) * 2018-06-13 2021-04-13 中山大学 一种替诺福韦艾拉酚胺与香草酸的共晶及其制备方法
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN110746461A (zh) * 2019-11-20 2020-02-04 江苏科本药业有限公司 一种替诺福韦衍生物盐及其制备方法和一种药物组合物
WO2021165995A1 (fr) 2020-02-20 2021-08-26 Cipla Limited Nouveaux sels et/ou co-cristaux de ténofovir alafénamide
WO2021192954A1 (fr) 2020-03-25 2021-09-30 ボッシュ株式会社 Dispositif de traitement de données d'événement et système d'évaluation de véhicule
US11667656B2 (en) 2021-01-27 2023-06-06 Apotex Inc. Crystalline forms of Tenofovir alafenamide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
EP0903341A1 (fr) * 1997-07-22 1999-03-24 Akzo Nobel N.V. Composés d'ortho-mercaptoaniline
KR100767432B1 (ko) * 2000-07-21 2007-10-17 길리애드 사이언시즈, 인코포레이티드 포스포네이트 뉴클레오티드 유사체의 전구 약물과 그것의 선택 및 제조 방법
MY140618A (en) * 2003-02-28 2009-12-31 Kowa Co Method for preparing acid addition salts of polyacidic basic compounds
US7459472B2 (en) * 2003-08-08 2008-12-02 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
RS55353B2 (sr) * 2011-08-16 2023-11-30 Gilead Sciences Inc Tenofovir alafenamid hemifumarat
US9676803B2 (en) * 2013-06-07 2017-06-13 Cipla Limited Efficient process for separation of diastereomers of 9-[(R)-2-[[(R,S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine
WO2015040640A2 (fr) * 2013-09-20 2015-03-26 Laurus Labs Private Limited Procédé amélioré pour la préparation de ténofovir alafénamide ou de sels pharmaceutiquement acceptables de celui-ci
EP3077404B1 (fr) * 2014-01-14 2020-10-07 Mylan Laboratories Ltd. Purification de ténofovir alafénamide et de ses intermédiaires
CN105085571A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 替诺福韦艾拉酚胺复合物及其制备方法和用途
CN104558036A (zh) 2014-12-11 2015-04-29 杭州和泽医药科技有限公司 一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法
CZ2015384A3 (cs) 2015-06-05 2016-12-14 Zentiva, K.S. Pevné formy Tenofovir alafenamidu

Also Published As

Publication number Publication date
AU2016277859A1 (en) 2017-12-14
US10155781B2 (en) 2018-12-18
US9777028B2 (en) 2017-10-03
WO2016205141A1 (fr) 2016-12-22
US20180127446A1 (en) 2018-05-10
JP2018524308A (ja) 2018-08-30
CA2987085A1 (fr) 2016-12-22
AU2019205989A1 (en) 2019-08-01
US20160368938A1 (en) 2016-12-22
EP4092037A1 (fr) 2022-11-23
AU2016277859B2 (en) 2019-08-01
HK1252631A1 (zh) 2019-05-31
EP3310797A1 (fr) 2018-04-25

Similar Documents

Publication Publication Date Title
MA46677A (fr) Co-cristaux, sels et formes solides de ténofovir alafénamide
MA41252A (fr) Formes solides d'un inhibiteur d'ask 1
MA56137A (fr) Sels de valbénazine et leurs polymorphes
DK3143011T3 (da) Deutererede heterocykliske forbindelser og deres anvendelse som billeddannende stoffer
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
DK3067075T3 (da) Vævsendoprotese samt fremgangsmåde til dens fremstilling
DK3283210T3 (da) Fremgangsmåde
FR3018191B1 (fr) Utilisations cosmetiques de la swertiamarine
BR112015015755A2 (pt) sistemas de imageamento de varredura
DK3189045T3 (da) Hidtil ukendte salte af nilotinib og polymorfer deraf
BR112016015712A8 (pt) método de tratamento de doenças hepáticas.
PL3430004T3 (pl) Postaci soli nilotynibu w stanie stałym
DK3317248T3 (da) Sacubitrilcalciumsalte
PT107944A (pt) Marcadores tridimensionais para axiografia e determinação de valores individuais
CL2018000896A1 (es) Dispersiones acuosas de polifosfato de calcio y potasio
FR3024647B1 (fr) Transat de puericulture
MA43166A (fr) Formulation de fviii
DK3285588T3 (da) Fremgangsmåde
ES1104405Y (es) Placa para facilitar la conexion de enchufes
MA45691A (fr) Formes solides d'inhibiteur de ttk
FR3039391B1 (fr) Orthese de contention
DK3206694T3 (da) Anvendelse af neridronsyre eller dens salt til behandling af osteoarthrose
FR3016113B1 (fr) Drague de coquillages
FR3027492B1 (fr) Egrappoir separateur-trieur de la vendange
ES1174633Y (es) Platilla correctora de juanetes